Anti-angiogenic compositions and methods of use
The present invention provides compositions comprising an anti-angiogenic factor, and a polymeric carrier. Representative examples of anti-angiogenic factors include Anti-Invasive Factor, Retinoic acids and derivatives thereof, and taxol. Also provided are methods for embolizing blood vessels, and eliminating biliary, urethral, esophageal, and tracheal/bronchial obstructions.
1 . A composition comprising:
(a) an anti-angiogenic factor; and
(b) a polymeric carrier.
2 . The composition of claim 1 , wherein said anti-angiogenic factor is Anti-Invasive Factor.
3 . The composition of claim 1 , wherein said anti angiqgenic factor is retinoic acid and derivatives thereof.
4 . The composition of claim 1 , wherein said anti-angiogenic factor is selected from the group consisting of Suramin, Tissue Inhibitor of Metalloproteinase-1, Tissue Inhibitor of Metalloproteinase-2, Plasminogen Activator Inhibitor-I and Plasminogen Activator Inhibitor-2.
5 . A composition comprising:
(a) taxol; and
(b) a polymeric carrier.
6 . The composition of claim 1 , wherein said composition has an average size of 15 to 200 lm.
7 . The composition of claim 1 , wherein said polymeric carrier is poly(ethylene-vinyl acetate) crosslinked with 40% vinyl acetate.
8 . The composition of claim 1 , wherein said polymeric carrier is poly(lactic-co-glycolic acid).
9 . The composition of claim 1 , wherein said polymeric carrier is polycaprolactone.
10 . The composition of claim 1 , wherein said polymeric carrier is polylactic acid.
11 . The composition of claim 1 , wherein said polymeric carrier is a copolymer of poly(ethylene-vinyl acetate) crosslinked with 40% vinyl acetate, and polylactic acid.
12 . The composition of claim 1 , wherein said polymeric carrier is a copolymer of polylactic acid and polycaprolactone.
13 . A method for embolizing a blood vessel, comprising delivering into said vessel a therapeutically effective amount of composition according to claims 1 - 12 , such that said blood vessel is effectively occluded.
14 . The method claim 13 wherein said blood vessel nourishes a tumor.
15 . A stent, comprising a generally tubular structure, the surface of which is coated with a composition according to claims 1 - 12 .
16 . A method for expanding the lumen of a body passageway, comprising inserting a stent into the passageway, the stent having a generally tubular structure, the surface of said structure being coated with a composition according to claims 1 - 12 , such that said passageway is expanded.
17 . A method for eliminating vascular obstructions, comprising inserting a vascular stent into a vascular passageway, the stent having a generally tubular structure, the surface of said structure being coated with a composition according to claims 1 - 12 , such that said vascular obstruction is eliminated.
18 . A method for eliminating biliary obstructions, comprising inserting a biliary stent into a biliary passageway, the stent having a generally tubular structure, the surface of said structure being coated with a composition according to claims 1 - 12 , such that said biliary obstruction is eliminated.
19 . A method for eliminating urethral obstructions, comprising inserting a urethral stent into a urethra, the stent having a generally tubular structure, the surface of said structure being coated with a composition according to claims 1 - 12 , such that said urethral obstruction is eliminated.
20 . A method for eliminating esophageal obstructions, comprising inserting an esophageal stent into an esophagus, the stent having a generally tubular structure, the surface of said structure being coated with a composition according to claims 1 - 12 , such that said esophageal obstruction is eliminated.
21 . A method for eliminating tracheal/bronchial obstructions, comprising inserting a tracheal/bronchial stent into the trachea or bronchi, the stent having a generally tubular structure, the surface of which is coated with a composition according to claims 1 - 12 , such that said tracheal/bronchial obstruction is eliminated.
22 . A method for treating a tumor excision site, comprising administering a composition according to claims 1 - 12 to the resection margin of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at said site is inhibited.
23 . A method for treating corneal neovascularization, comprising administering a therapeutically effective amount of a composition according to claims 1 - 12 to the cornea, such that the formation of blood vessels is inhibited.
24 . The method of claim 23 , wherein said composition further comprises a topical corticosteroid.
25 . A method for inhibiting angiogenesis in patients with non-tumorigenic, angiogenesis-dependent diseases, comprising administering a therapeutically effective amount of a composition comprising taxol to a patient with a non-tumorigenic angiogenesis-dependent disease, such that the formation of new blood vessels is inhibited.
26 . A method for embolizing a blood vessel in a non-tumorigenic, angiogenesis-dependent diseases, comprising delivering to said vessel a therapeutically effective amount of a composition comprising taxol, such that said blood vessel is effectively occluded.
27 . A method for expanding the lumen of a body passageway, comprising inserting a stent into the passageway, the stent having a generally tubular structure, the surface of said structure being coated with a composition comprising taxol, such that said passageway is expanded.
28 . A method for eliminating vascular obstructions, comprising inserting a vascular stent into a vascular passageway, the stent having a generally tubular structure, the surface of said structure being coated with a composition comprising taxol, such that said vascular obstruction is eliminated.
29 . A method for eliminating biliary obstructions, comprising inserting a biliary stent into a biliary passageway, the stent having a generally tubular structure, the surface of said structure being coated with a composition comprising taxol, such that said biliary obstruction is eliminated.
30 . A method for eliminating urethral obstructions, comprising inserting a urethral stent into a urethra, the stent having a generally tubular structure, the surface of said structure being coated with a composition comprising taxol, such that said urethral obstruction is eliminated.
31 . A method for eliminating esophageal obstructions, comprising inserting an esophageal stent into an esophagus, the stent having a generally tubular structure, the surface of said structure being coated with a composition comprising taxol, such that said esophageal obstruction is eliminated.
32 . A method for eliminating tracheal/bronchial obstructions, comprising inserting a tracheal/bronchial stent into the trachea or bronchi, the stent having a generally tubular structure, the surface of said structure being coated with a composition comprising taxol, such that said tracheal/bronchial obstruction is eliminated.
33 . A method for treating a tumor excision site, comprising administering a composition comprising taxol to the resection margin of a tumor subsequent to excision, such that the local recurrence of cancer and the formation of new blood vessels at said site is inhibited.
34 . A method for treating corneal neovascularization, comprising administering a therapeutically effective amount of a composition comprising taxol to the cornea, such that the formation of new vessels is inhibited.
35 . A pharmaceutical product, comprising:
(a) taxol, in a container; and
(b) a notice associated with said container in form prescribed by a governmental agency regulating the manufacture, use, or sale of pharmaceuticals, which notice is reflective of approval by said agency of said taxol, for human or veterinary administration to treat non-tumorigenic angiogenesis-dependent diseases.